BACKGROUND: Disseminated @entity5 cells (DTC) in the bone marrow (BM) of primary @entity0 ( @entity0 ) @entity1 are a promising surrogate marker of micrometastatic spread and an independent predictor of poor prognosis for @entity66 ( @entity66 ) and @entity1349 ( @entity1349 ). The present study aims to analyze DTCs as an independent prognostic factor for @entity66 / @entity1349 in @entity5 biology and @entity5520 treatment. METHODS: A total of 504 @entity1 with operable primary @entity0 and a median observation time of 72.3  months [lower quartile (LQ) 58.1; upper quartile (UQ) 82.8] have been included. DTCs were detected via immunohistochemistry as @entity2355 positive cells in the BM of 59.13  % (298 of 504) of the @entity1 . The immunophenotyping of @entity5 cells was achieved immunohistochemically as well. RESULTS: For luminal A/B @entity189 @entity1 , we observed a significant benefit of BM DTC negativity with respect to @entity66 (luminal A, P  =  0.0498; luminal B, P  =  0.0224). In triple-negative @entity1 , DTC-negative BM was associated with a longer @entity1349 (P  =  0.0326). In a multivariate Cox survival analysis relating to @entity66 and @entity1349 , the DTC status was identified as an independent prognostic factor for @entity66 in luminal A/B @entity0 (P  =  0.0071). A multivariate Cox survival analysis among DTC-positive @entity1 with luminal immunophenotype showed @entity5520 application (P  =  0.0326) to be an independent prognostic factor for @entity66 . CONCLUSIONS: The findings of our multivariate analyses reveal BM DTC positivity as an independent risk factor for @entity66 particularly in luminal A/B @entity0 @entity1 . This might be a novel criterion for the identification of candidates most likely to benefit from additional adjuvant therapy possibly including @entity171 .

@entity5 Cells in the Bone Marrow of @entity1 with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for XXXX Treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC'] @entity66 :: ('MESH:D004194', 'Disease') :: ['DFS', 'disease-free survival'] @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate'] @entity2355 :: ('4582', 'Gene') :: ['MUC-1'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity5520 :: (D004164,Chemical) :: ['Bisphosphonate']
